title: Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy.
abstract: BACKGROUND
  High-dose chemotherapy (HDC) has been widely utilized in high-risk breast cancer, but it may induce cardiac toxicity. Cardiac dysfunction may become evident weeks or months after HDC and, to date, no early markers of myocardial injury that are able to predict late ventricular impairment are available. We investigated the role of plasma troponin I (TnI) in this setting.
  
  
  METHODS
  We measured TnI plasma concentration after HDC in 211 high-risk breast cancer women (46 +/- 11 years, mean +/- SD). According to TnI value (< 0.5 or > or = 0.5 ng/ml), patients were allocated into a troponin positive (TnI+; n = 70) and a troponin negative (TnI-; n = 141) group. All patients underwent left ventricular ejection fraction (LVEF, Echo) examination during the following 12 months.
  
  
  RESULTS
  LVEF progressively decreased in the TnI+ group but not in the TnI- group. In TnI+ patients a close relationship between the TnI increase, as well as the number of positive TnI assays, and the maximal LVEF decrement, was found (r = -0.92, P < 0.0001 and r = -0.93, P < 0.0001, respectively).
  
  
  CONCLUSIONS
  In our population, the elevation of TnI soon after HDC accurately predicts the development of future LVEF depression. In this setting, TnI can be considered a sensitive and reliable marker of myocardial damage with relevant clinical and prognostic implications.
authors.affiliation: Cardiology Unit, Istituto Europeo di Oncologia, University of Milan, Italy. daniela.cardinale@ieo.it
authors.forename: D
authors.initials: D
authors.lastname: Cardinale
authors.forename: M T
authors.initials: MT
authors.lastname: Sandri
authors.forename: A
authors.initials: A
authors.lastname: Martinoni
authors.forename: E
authors.initials: E
authors.lastname: Borghini
authors.forename: M
authors.initials: M
authors.lastname: Civelli
authors.forename: G
authors.initials: G
authors.lastname: Lamantia
authors.forename: S
authors.initials: S
authors.lastname: Cinieri
authors.forename: G
authors.initials: G
authors.lastname: Martinelli
authors.forename: C
authors.initials: C
authors.lastname: Fiorentini
authors.forename: C M
authors.initials: CM
authors.lastname: Cipolla
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009202:Cardiomyopathies / Q000097:blood* / Q000139:chemically induced*; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006334:Heart Function Tests; D006801:Humans; D016015:Logistic Models; D008875:Middle Aged; D009367:Neoplasm Staging; D011336:Probability; D011446:Prospective Studies; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D015996:Survival Rate; D019210:Troponin I / Q000032:analysis / Q000097:blood*
chemical_list: D015415:Biomarkers; D019210:Troponin I